My career has focused on cell biology and the development and application of systems biology approaches to understand cellular mechanisms. In 2014, I began apply these skills to the challenging problem of blood-based diagnostics. Identification of blood biomarkers is challenging because of very weak signal to noise ratios. Using cultured cells as biosensors can overcome this problem by capitalizing on the natural ability of cells to detect and respond to weak signals in noisy environments. Over the past 8 years at PreCyte, I have lead the development of the indicator cell assay platform (iCAP), a novel diagnostic tool that uses cells as biosensors to detect and respond to disease indicators in blood. We use machine learning tools to identify cell responses that can robustly indicate early stage disease in the patients. We are initially applying the assay for early detection of lung cancer and Alzheimers disease.
Elevating Bloodbased Diagnostics Using Cells as Biosensors
We are developing a novel tool for bloodbased diagnostics called the indicator cell assay platform (iCAP). The assay uses cultured cells as biosensors that detect and respond to weak disease signals in patient blood samples and machine learning tools to find reliable disease indicators in the cell response.
Track Chair: Hakan Sakul, Pfizer